Company intelligence / Profile preview

Yuekang Pharmaceutical

Ownership: Private
Development stage: Phase 3

Overview

Yuekang/Youcare has multiple approved products in China and internationally. Its pipeline includes both marketed generics/traditional medicines and innovative drugs such as a broad-spectrum anti-coronavirus peptide inhaler currently in clinical trials. The company also runs a Phase III trial of YK‑029A tablets for NSCLC with EGFR ex20ins mutations via its Hainan subsidiary. In the first three quarters of 2024 it reported revenues of nearly ¥3 billion (~$420 million)

Therapeutic areas: Men's HealthPulmonologyOncologyEndocrinologyCardiovascularInfectious Diseases
Modalities: Small moleculesmRNA vaccinessiRNApeptide drugsherbal medicinesbiological drugs
Industry: Biotech

Drug pipeline

12 assets

Huoxin Pill

11 more assets in the full pipeline.

Partnerships

Institute of Pathogenic Biology Chinese Academy of Medical Sciences

Beyond the preview

Go deeper on Yuekang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuekang Pharmaceutical.